SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " clinical " 971 found 🔀 AI-powered Shuffle
Paging Dr. Google … Dr. GPT is in the house
These are the primary platforms currently battling for dominance in the $36 billion clinical AI market
Paging Dr. Google … Dr. GPT is in the house
These are the primary platforms currently battling for dominance in the $36 billion clinical AI market
How to get clinical and ops staff to adopt new tech – a major health IT challenge
"It's coming at them at a very fast pace," says Broward Health CIO Steven Travers, who advises healthcare organizations to ensure new tools fit both what an organization is is trying to accomplish, and the existing processes of frontline staff.
Cityblock Health Appoints New Chief Health Officer to Advance Technology-Enabled Clinical Care Model for Government Programs
/PRNewswire/ -- Cityblock Health, a value-based healthcare provider for Medicaid and dually eligible beneficiaries, announced the appointment of their new...
Achieving Health Equity Demands Shift to Structural Change
Advancing health equity in medicine requires a clear-eyed understanding of history, a rejection of race-based clinical assumptions and a commitment to transform research into practice, said Dr. Joseph L. Wright, senior vice president and chief health equity officer of the American Academy of Pediatrics (AAP), in his keynote address for Weill Cornell Medicine’s eight annual Diversity Week.
Using AI To Personalize Healthcare–Without Losing Patient Trust
In this week’s edition of InnovationRx, we look at the opportunities and challenges of using AI to personalize healthcare and speed up clinical trials, the future of genetic medicine, another big Lilly acquisition, and more.
UM Health-Sparrow named among the top maternity hospitals in the country
UM Health-Sparrow has been named one of the best hospitals in the United States for maternity care, earning a four-ribbon designation on Newsweek’s “America’s Best Maternity Hospitals 2026.”
Paradigm Health Launches SPIRE to Accelerate Late-Phase Clinical Evidence Generation
/PRNewswire/ -- Paradigm Health today announced SPIRE — Scalable Platform for Integrated Research & Evidence — a new model for post-approval and late-stage...
Mechanohealth: Where life science meets physical forces for health innovation
Integrating mechanobiological principles into disease pathogenesis, therapeutic development, and tissue engineering is reshaping our understanding of biological systems and accelerating the advancement of mechanotherapy and mechanohealth. This field reveals how mechanical cues regulate cellular behavior, such as force transmission along integrin-nucleus pathways and collective cell migration, and tissue functions. In doing so, mechanobiology connects fundamental research with clinical applications, from limiting cancer metastasis and fibrosis to promoting bone regeneration and maintaining vascular homeostasis. Building on discussion from the Inaugural International Conference on Mechanobiology (ICM) 2025, integrating mechanobiological research with clinical strategies offers new opportunities to address unmet needs, including personalized anti-fibrotic interventions or precision bone regenerative therapies. At the same time, it supports the broader concept of mechanohealth -- a paradigm focused on preserving the physiological mechanical balance within tissues.
Dr. Aditya Bardia elected to American Society for Clinical Investigation
Each year, the organization selects up to 100 physician-scientists in recognition of their outstanding contributions to research and patient care.
Opinion | The University of Minnesota’s vision for health care is flawed
"Based on our years of experience with the U and its health sciences, we would argue that moving the clinical practice of the university’s medical school back inside the university is a bad idea," the authors write.
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation
Bracco Imaging today announced a strategic alliance with NYU Langone Health to advance innovation in medical imaging through the signing of a multi-year Master Research Agreement (MRA). By combining resources, scientific capabilities and complementary expertise, the collaboration aims to accelerate the development and optimization of advanced imaging technologies, enhancing clinical insights and contributing to improved patient management.
Advancing epidemic and pandemic preparedness through research readiness: SEAR Unity Studies Network Sites chart the way forward in 2026
On 25 March 2026, WHO Regional Office for the South‑East Asia Region (SEARO) convened the first meeting of the SEAR Chapter of the Unity Studies Network Meeting in 2026 to take stock of progress and plan next steps for strengthening epidemic and pandemic preparedness across the Region. The meeting focused on reviewing the ongoing adaptation of selected, standard Unity Study methodologies, sharing field implementation experiences from 2025, and identifying key priorities to guide collaborative work in 2026.Held virtually, the meeting brought together representatives from six Unity Studies network sites across five countries (Bangladesh, India, Nepal, Sri Lanka, and Thailand) as well as participants from all three levels of WHO.The meeting took place against the backdrop of ongoing regional efforts in South‑East Asia to strengthen early investigations and studies for epidemic and pandemic preparedness, with a focus on pandemic influenza and other emerging respiratory pathogens with epidemic and pandemic potential. In this context, and as part of preparedness for the rapid generation of evidence, the WHO Health Emergencies Programme in SEAR (WHE/SEAR) encourages Unity Studies sites to adapt prioritized, standardized Unity Study protocols to their national contexts. This approach supports the generation of timely and reliable evidence to inform public health decision‑making during epidemics and pandemics.These efforts are supported through a combination of experience sharing, participation in the global Unity Studies network webinars, capacity‑building of the national public health workforce, and regional collaboration that promotes inter‑country, inter‑agency, and inter‑ministerial action. In parallel, sites are encouraged to explore diversified funding sources to help sustain research preparedness over the long term.Discussions highlighted the importance of WHO’s catalytic financial support through the Pandemic Influenza Preparedness (PIP) Partnership Contributions (PIP‑PC). When combined with national and institutional resources, this support enables countries and sites to maintain continuity of activities at a core level and remain prepared to respond rapidly and effectively to future epidemics and pandemics.Regional and Global Updates: Opening the session, Dr Pushpa Ranjan Wijesinghe, Programme Area Manager, Pandemic and Epidemic Management (PEM) Unit, WHO Health Emergencies Programme, highlighted the progress made in operationalizing the Unity Studies Network across the Region and acknowledged the collaborative efforts of WHO at all three levels, together with country unity studies sites. He emphasized the availability of limited but catalytic funding through the Pandemic Influenza Preparedness (PIP) Partnership Contribution (PIP‑PC) workplan at SEARO to sustain network activities in 2026, while encouraging sites to leverage additional funding sources to expand implementation.Representing SEARO, Dr Ashok Basnet, consultant, Pandemic Influenza Preparedness reported that, at the regional level, the Unity Studies Network currently includes six sites across five countries: Bangladesh, India, Nepal, Sri Lanka, and Thailand. He noted that in 2025, catalytic funding supported protocol adaptation, training, and pilot implementation. In addition, a regional Unity Studies symposium held during the Global Public Health Summit in Sri Lanka strengthened and advocated collaboration between the Unity Studies site, national decision‑making forum, relevant technical units of the ministry of health, WHO and other partners.The symposium also highlighted the role of early investigations and studies as a key component of a multi‑source surveillance system needed at country level to generate a broad range of evidence. It underscored the critical role of country Unity Studies sites and similar research entities in generating evidence to support public health decision‑making during epidemics and pandemics.Participants of the WHO GISRS Unity Studies Sites Network- SEAR Chapter Meeting 2026 (Photo credit- PEM/WHE/SEARO). SEARO also updated participants on ongoing efforts to develop a regional Unity Studies webpage and to promote participation in global knowledge‑sharing platforms, including webinars and the WHO Community of Practice. Priorities for 2026 include supporting the implementation of Unity protocols, strengthening collaboration and experience sharing across sites, documenting and publishing findings, integrating Unity Studies activities as a component of multi-source national surveillance systems, and building workforce capacity.Dr Nickle Boddington of the Global Influenza Programme (GIP) at WHO Headquarters, which coordinates the Unity Studies Network globally, provided updates on global Unity Studies activities, noting that the network has expanded to 16 sites worldwide. New and updated protocols, including rapid clinical severity assessment tools and standardized data platforms, are being developed to support implementation. The global Community of Practice has also been launched to facilitate technical exchange, and continued support will be provided to sites for protocol adaptation, ethical approvals, and readiness for early investigation during outbreaks. Updates from Unity Studies sites in SEAR in 2025Unity Studies sites shared progress and experiences in implementing protocols across diverse country contexts. Sites initiated activities in 2025 using catalytic funding from SEARO, complemented by the mobilization of internal national resources. The Institute of Epidemiology, Disease Control and Research (IEDCR), Bangladesh, reported the adoption and piloting of investigation protocols on non‑seasonal influenza and emerging respiratory diseases during recent avian influenza outbreaks, demonstrating a multi‑source funding approach involving government, WHO and One Health partners.The Hamdard Institute of Medical Sciences and Research (HIMSR), New Delhi, India, highlighted the piloting of household transmission investigation studies, the expansion of the national Unity Studies network, and the contribution of study findings to global evidence through published outputs. The All-India Institute of Medical Sciences (AIIMS), New Delhi, India, shared experiences from large‑scale seroprevalence studies conducted during the COVID‑19 pandemic, recent efforts to strengthen national Unity network sites through training activities, and plans to initiate multi‑centre studies on respiratory viruses.Similarly, Prince of Songkla University, Thailand, highlighted its experience in developing integrated surveillance and diagnostic protocols for multiple respiratory pathogens, enhancing readiness for targeted investigations of emerging threats. The University of Sri Jayewardenepura, Sri Lanka, reported ongoing engagement with the Ministry of Health and exploration of additional funding sources to initiate studies. Meanwhile, the National Public Health Laboratory, Nepal, provided updates on continued coordination with national stakeholders to initiate implementation, despite delays related to the country context.Across sites, shared experiences underscored the importance of protocol adaptation, multisectoral collaboration, and sustainable funding to operationalize Unity Studies and generate evidence for public health action.Discussions and Way ForwardThe meeting reinforced key priorities for 2026, including strengthening unity studies protocol implementation, enhancing collaboration, knowledge sharing, integrating research as a component of national multi-source surveillance systems, and ensuring that generated evidence informs public health decision‑making. Participants also emphasized the importance of documentation, visibility, and leveraging multiple funding sources, and agreed on the following action points.Unity Studies Sites and WHO Country Offices:Advance adoption and implementation of at least one Unity protocol, continuing activities initiated in 2025 with catalytic funding, supplemented with other sources of funding where feasible.Document site-specific experiences, outcomes, and lessons learned; participate in regional and global knowledge-sharing platforms including WHO webinars and the Community of Practice.Work closely with ministries of health to establish unified national platforms for translating generated evidence into national public health decision-making. WHO Country Offices may facilitate technical support and complementary, synergistic funding opportunities where feasible. WHO Regional OfficeCoordinate with WHO Country Offices to support implementation of core unity studies activities by network sites through catalytic funding and provide technical guidance and virtual engagement opportunities throughout 2026.Facilitate the participation of all Unity Studies sites in the regional meeting on Unity Studies implementation in October 2026, to be held back‑to‑back with the Annual SEAR Regional PIP‑PC Meeting; develop and host a SEAR Unity Studies website; and mobilize support from academic institutions within the SEAR Unity Studies Network to support the development of regional manuscripts that showcase Unity Studies activities to scientific audiences and promote knowledge‑sharing.Explore complementary funding opportunities and partnerships to sustain and expand network activities across the Region.WHO HeadquartersProvide global technical guidance, updated protocols, and toolkits to support the implementation of Unity Studies in SEAR.Facilitate engagement of SEAR sites in global webinars, the Community of Practice, and opportunities to showcase their work.Support joint publications, inclusion of SEAR experiences in global outputs, and identification of additional funding and collaborative opportunities to strengthen Unity Studies activities.
NYU Langone Health neurologists present latest clinical findings and research at AAN 2026
This year’s meeting features more than 80 presentations from Department of Neurology faculty. Here are notable highlights: practical strategies to counter harmful medical myths and misinformation, phase 3 clinical results for a novel epilepsy medication, and the barriers patients with disabilities face while navigating outpatient facilities.
Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental Health Conditions
President Donald Trump has signed an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics, a move aimed at making substances such as psilocybin, ibogaine, LSD and MDMA more readily available to patients in clinical settings. The move will “dramatically accelerate access to new medical research and treatments based […]
The science behind the peptide craze
The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence
Why Promising Cancer Drugs Failed: Scientists Uncover the Missing Piece
A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials.
Spectrum Science Appoints Lisa Talbot to Lead Communications Business
/PRNewswire/ -- Spectrum Science, an independent, full-service, strategic platform offering integrated clinical, commercial, and communications services, today...
Spectrum Science Appoints Lisa Talbot to Lead Communications Business
/PRNewswire/ -- Spectrum Science, an independent, full-service, strategic platform offering integrated clinical, commercial, and communications services, today...
Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis underway Private financing of up to $60M (with $10M of such amount upfront) offering of common stock and milestone-based and three-year warrants completed on April 15, 2026 supporting operations
BizTalk: Innovators and Healthcare Professionals Convene in Arlington
Leaders in healthcare, technology and research gathered in Arlington last month to explore how artificial intelligence is shaping the future of patient care. The Healthcare + AI Forum, held March 26 at Arlington Economic Development (AED), brought together healthcare professionals, researchers, entrepreneurs and industry leaders to discuss real-world applications of AI in healthcare, from clinical
Re:Cognition Health Delivers Landmark International Clinical Trial to Explore Whether a Simple Finger-prick Blood-based Biomarker Test Can Provide Earlier Alzheimer's Diagnosis
Re:Cognition Health, a global leader in new treatments for Alzheimer's Disease, is delivering an international clinical trial to evaluate whether a simple finger-prick blood test can revolutionize how Alzheimer's disease is diagnosed. Compared with the current invasive and expensive diagnostic methods, this approach could provide a scalable solution for an earlier, easier, more accurate, affordable, and accessible diagnostic method. Re:Cognition Health will help enroll approximately 1,000 partic
Osara Health Publishes New Peer-Reviewed Study Demonstrating Clinically Meaningful Improvements in Physical and Mental Health for People With Cancer
/PRNewswire/ -- Osara Health, a global digital health company focused on the human experience of cancer care, today announced a new peer-reviewed study showing...
UT Health San Antonio Multispecialty and Research Hospital treats first clinical trial participant in novel cancer study - UT Health San Antonio
Milestone paves the way for advancements in cancer care, innovation and patient care in San Antonio and South Texas Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu Content by Jane Alvarez-Hernandez SAN ANTONIO, April 15, 2026 – UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer […]
QPS Missouri expands clinical research to patients in Springfield
Springfield residents with chronic conditions can now join more clinical studies as QPS Missouri expands its research efforts.
Stanford HAI 2026 AI Index: AI posts gains in science and medicine while often struggling to read a clock
Stanford HAI’s 2026 AI Index paints a split-screen picture for R&D. In the report’s science chapter, “frontier models outperform human chemists on average on ChemBench,” yet “score below 20% on replication in astrophysics and 33% on Earth observation questions.” In medicine, the report reaches a similarly mixed conclusion, saying AI is transforming clinical care, but…
Can AI Fix the Mental Health Crisis?
Demand is outpacing care. AI tools are already filling the gap. But are they safe, effective, and ready for clinical practice?
Analysis: Rogers still has more to prove
Morgan Rogers is attracting a lot of attention and the growing expectation is he will leave Aston Villa in the summer. Villa will likely need to sell a star player, regardless of whether they qualify for the Champions League, and Rogers is their best asset - especially with Boubacar Kamara out injured. An impressive World Cup would also strengthen Villa's hand but the England forward needs to show more of a clinical nature throughout the pitch.
‘Aggie docs’ coming to San Antonio’s South Side with new medical collaboration
Texas A&M medical students will begin clinical rotations at University Health’s Palo Alto Hospital and Vida clinic in 2028.
How aggressive breast cancer turns off the immune system
Researchers are launching a new project to crack the mystery of aggressive breast cancer, where predicting disease progression remains a major hurdle. By studying how tumors interact with and suppress the immune system, scientists aim to identify new biomarkers that reveal how the cancer evolves. Using real patient samples, the team hopes to turn earlier discoveries into practical clinical tools. The goal: more precise, personalized treatments that can outsmart even the most dangerous tumors.
5th Annual Clinical Mental Health Counseling Virtual Conference
The Commonwealth University of Pennsylvania - Lock Haven, Department of Counseling & Educational Leadership, Clinical Men
Celebrating 25 Years of Caldwell University’s Master’s degree in Clinical Mental Health Counseling with Art Therapy Concentration
Caldwell, NJ – Caldwell University’s Master’s degree in Clinical Mental Health Counseling with Art Therapy Concentration program has been molding students into dynamic mental health professionals for 25 years. This […]
BioFest Days event spotlights innovation at Center for Brain Health - UT Health San Antonio
The BioFest Days brought the community together April 7, for an evening of discovery and connection at the UT Health San Antonio Center for Brain Health. Hosted as part of the 12-day, citywide celebration of biomedical advancement organized by BioMed SA, the event invited attendees to explore how research, clinical care and community involvement […]
3L Rachel Sadler Charts Path in Brain Health, Technology, and Policy Through UC Law SF’s Health Law Concentration - UC Law San Francisco (Formerly UC Hastings)
3L Rachel Sadler studies health law and policy at UC Law SF while researching the legal implications of neurotechnology and other emerging tools that may affect human cognition. 3L student Rachel Sadler shares how UC Law SF’s Health Law Concentration prepared her for a career focused on the intersection of brain health, government policy, and technology. Gained a detailed understanding of how U.S. health care is regulated and where policy reform is needed through coursework and research. Interned with state and federal agencies that regulate health care services and worked with a major health care provider’s bioethics department. Plans to pursue a career focused on protecting cognitive liberty and mental privacy as new technologies reshape healthcare. 3L Rachel Sadler: The Health Law Concentration has given me fluency in one of the most complex regulated industries and the tools to become an effective advocate for better health policy. Before coming to law school, I spent a decade teaching and working with teachers and administrators on high school programming for multilingual learners. Healthcare kept emerging as the most powerful driver of student outcomes. I wanted to understand how to make effective policy change in this area and how to use existing law to defend people’s health rights in California. Through the concentration’s coursework, I gained a sophisticated understanding of how U.S. healthcare is regulated. I also learned where the pressure points for reform exist. The courses gave me space to develop what became my central research interest: how law and policy can be built to protect human cognition and healthy brain development, particularly regarding new technologies such as generative AI and neurotechnology. The health law faculty were instrumental in that process, genuinely invested in helping me and other students define and pursue our own intellectual vision. During law school, I interned at the General Counsel’s Office for Region IX of the U.S. Department of Health and Human Services. I also externed at the California Department of Justice’s Health, Education and Welfare Division. Additionally, I externed at Kaiser Permanente Northern California’s Bioethics Department. Alongside those placements, I conducted extensive independent research on mental privacy and emerging neurotechnology, working closely with Professors Emily Murphy and George Horvath. That research became the throughline of my law school experience and the foundation of my current policy focus. I must also credit Nicole Ozer of the Center for Constitutional Democracy (CCD), whose deep knowledge of California privacy law and the public-interest privacy landscape deeply informed my work. I currently serve a research assistant with the CCD, where I spearhead the development of K-12 educational resources in partnership with law faculty and students. I’ve found UC Law SF to be an ideal place for second-career, nontraditional students. There is a tremendous diversity of life and career experience here, and I felt fully welcomed into the community, despite returning as a student at a different stage of life. I came to law school wanting to promote equity in California’s healthcare system. I am leaving with a sharper and more specific ambition: to build a policy career focused on protecting cognitive liberty and mental privacy from technological intrusion. This is both an urgent and underserved area of law, and I want to be part of defining this landscape going forward. Whether as a practicing attorney or a policy advisor, I plan to work on these issues after law school. I strongly recommend UC Law SF and the Health Law Concentration. When I arrived in law school, I worried the concentration would be narrow and that my non-clinical background would be a disadvantage. The opposite was true. The health law faculty thinks about health expansively, encompassing social determinants of health, structural inequity, and emerging technologies alongside the regulatory mechanics of the industry. The faculty are accessible, intellectually generous, and genuinely invested in students’ development. I found my research vision here, and I deeply appreciate the concentration’s role in this. The Evidence of Success series highlights UC Law SF students as they share how the College’s opportunities equip them with the experience, skills, and confidence to excel in the legal profession.
Abortion Pill’s Safety Called into Question in Congressional Actions Based on Misleading Data — The Monitor
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safety. And competing interpretations of what censorship and free speech mean are impacting how health misinformation is moderated.
SGMC Health Honors Lane with Safe Care Award
SGMC Health recognized Peter Lane, a certified clinical perfusionist, with the Safe Care Award for his exceptional attention to detail, clinical expertise, and unwavering commitment to advocating for patients. During open‑heart surgery, clinical […]
University, UNC Health unveil SHIRE health care innovation platform
The Secure Health Informatics Research Environment will speed up the responsible use of artificial intelligence with clinical data.
April 8, 2026: Behavioral Science-Based Electronic Health Record Tools, in This Week's Rethinking Clinical Trials Grand Rounds
In this Friday’s Rethinking Clinical Trials Grand Rounds, Julie Lauffenburger of Harvard Medical School will present on the “Impact of Behavioral Science-Based Electronic Health Record Tools on Deprescribing for Older […]
Executive Summary: A Patients’ Bill of Rights To Lower Health Care Costs
CAP’s plan would limit unjustified premium increases; reduce deductibles by reining in outlier hospital prices; and replace prior authorization with independent, evidence-based clinical review to lower health care costs and increase access to timely care.
SDSU public health programs, speech-language science rank among nation
Four top-25 programs include epidemiology and clinical psychology.
SDSU public health programs, speech-language science rank among nation
Four top-25 programs include epidemiology and clinical psychology.
Pediatric ICU nurse brings clinical insight to global health policy analysis | Harvard T.H. Chan School of Public Health
Heesu Shin, SM ’26, helped take care of kids at his hospital in South Korea. Now, he’s working to help them on a larger scale through his research.
Immunic COO highlights the importance of science-led innovation to mark World Health Day
Immunic Inc (NASDAQ:IMUX, FRA:10VA) chief operating officer Jason Tardio talked with Proactive's Stephen Gunnion about the importance of science-led innovation in tackling neurological diseases, particularly multiple sclerosis, on World Health Day 2026. Tardio highlighted that the biotech industry is fundamentally grounded in scientific research and data, noting that “everything we do is rooted in science.” He explained that Immunic is focused on developing innovative therapies designed to improve patient outcomes and address significant unmet medical needs. The discussion centred on multiple sclerosis (MS), a complex neurological disease that continues to present challenges despite decades of progress. Tardio pointed out that while advancements have been made, “the disease is not solved for,” with many patients still experiencing disability progression and requiring safer, more tolerable treatments. He emphasised the urgent need for innovation, particularly in progressive forms of MS where treatment options remain extremely limited. Immunic’s lead asset, vidofludimus calcium, is being developed as a novel approach aimed at addressing the full spectrum of the disease. Tardio also reinforced the broader mission of the healthcare and biotech sectors, stating that the ultimate goal is to help individuals “live a better quality of life” and “a healthier life longer.” Watch the full interview to learn more about Immunic’s approach to advancing MS treatment through science. For more videos like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss an update. #Immunic #MultipleSclerosis #BiotechInnovation #Healthcare #MSResearch #DrugDevelopment #ClinicalTrials #Neurology #WorldHealthDay #ScienceDriven #VidofludimusCalcium #PharmaNews #BiotechNews
State’s first Health Learning Lab opens at Waianae High School
The lab provides students with hands-on clinical skills training in a modern setting and supports certificate programs designed to lead directly to entry-level healthcare jobs.
AI finds drug safety signals in clinical notes
Large language models were tested on cancer patient notes from two academic medical centers and seven drug trials.
Auraria Health Center offers same-day appointments and free services for faculty and staff
Same-day medical appointments and no-cost health services are available to faculty and staff members through the Health Center at Auraria, offering a convenient alternative to long wait times for primary care. The center offers a broad range of clinical services, including primary care, psychiatric support and telehealth appointments. Faculty and staff can also be seen for sick visits, including infections, […]
‘Building a better future’: UCLA receives $33 million to address LA’s youth mental health crisis
The Ballmer Group investment will support academic and clinical training that will bring more Bruin practitioners into local communities.
Embedded mental health clinical interns quickly connect people to support
Counseling Service of Addison County’s embedded master’s-level clinical internship program connects people to services, offering support from a familiar face within a trusted agency. Interns gain close supervision and guidance from expert staff in an established Community Mental Health Agency.
Senior Spotlight 2026: For this aspiring physician, computer science is ‘empowering’ asset
Rice senior Pankti Mehta is channeling her drive to improve how people access and experience health care by combining computer science with hands-on clinical insight.
East Lansing Insider Podcast: A Conversation with Acorn Health
On this week's podcast, ELi Deputy Editor Anna Liz Nichols talks about autism awareness and acceptance with Paul Doher, national director of clinical quality for Acorn Health.
A global consensus establishes a basis for measuring and improving gut health
While “gut health” is becoming a popular term, mainly in media and marketing claims but also in the clinical context, researchers have not yet nailed down a definition. Now, a global group of 13 scientists and clinicians updates a consensus definition of gut health and implications from bench to bedside.
Mercy Health outsources 24/7 critical systems monitoring
The Catholic-run healthcare provider has moved to managed monitoring of its clinical integration systems to improve incident response and reduce downtime across its services.
Fayette County Annual Report Highlights Local Public Health Efforts
Article presented by McDonald’s, I’m Lovin’ It! … Fayette County Public Health (FCPH) has released its 2025 Annual Report, showcasing the department’s work to protect health, prevent disease, and promote wellness across the community. The report highlights the impact of public health services delivered throughout the year, including clinical care, environmental health, school-based services, emergency preparedness, and community outreach initiatives. In
Preparing the Next Generation of Alcohol and Drug Counselors
UNO’s Clinical Mental Health Counseling program is expanding its reach and impact by offering students a pathway to dual licensure in both mental health and substance use counseling. In just two additional courses beyond their required coursework, students can become eligible for Nebraska’s Provisional Licensed Alcohol and Drug Counselor (PLADC) credential.
Wearable Health Devices in Clinical Care
Wearable health devices like smartwatches may be increasingly used in clinical care, as FDA policy shifts may accelerate adoption.
Iterative Health, US Heart & Vascular Partner to Advance Community-Based Cardiovascular Research
April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance research through community-based innovation in cardiovascular care. "Clinical research is one of the most powerful ways we expand access, improve patient outcomes, and shape the future of cardiovascular care," said Robbie Allen, chief executive officer of US Heart & Vascular. "By partnering with Iterative Health, we are strengthening our ability to bring innovative therapies directly into the communities we serve. This collaboration ensures our physicians and patients have access to leading-edge trials while allowing US Heart & Vascular to remain focused on delivering exceptional, physician-led care." Under the agreement, USHV research sites will join Iterative Health’s global site network, which now spans over 100 sites across three continents. The companies share a commitment to advancing clinical research as a driver of care innovation, and this collaboration represents a major milestone for both organizations, strengthening USHV's leadership in community-based cardiovascular research and expanding Iterative Health's multispecialty focus beyond GI, hepatology, and obesity into cardiology. USHV clinical research sites will gain access to Iterative Health's centralized operational backbone, providing end-to-end support across clinical research operations, services, business development, technology innovation, and corporate functions. The strategic partnership reduces operational complexity and unlocks growth potential for USHV research sites while enabling all USHV physicians to expand access to cutting-edge therapies to the thousands of patients they serve annually. "Innovation in cardiovascular medicine shouldn't be limited to a few academic centers," said Thomas Waggoner, DO, MD, RPVI, FACC, FSCAI, FSVM, RPVI, Structural Cardiologist and Medical Director for Clinical Research at Pima Heart & Vascular, and USHV Physician Champion for Clinical Research. "By expanding community-based research across USHV, we're ensuring more patients have access to clinical trials and breakthrough therapies close to home, where trusted relationships with their physicians already exist." This alliance reinforces Iterative Health's standing as the definitive research partner across specialized therapeutic areas, now spanning GI, hepatology, obesity, and cardiovascular care. Trusted by many of the nation's leading provider organizations and biopharma sponsors, Iterative Health's global site network delivers industry-leading trial performance, accelerating life-changing therapies to market at scale. "Entering cardiology through our strategic partnership with US Heart & Vascular is a defining moment for Iterative Health and reflects the strength of our site-serving model," said Jonathan Ng, founder and CEO of Iterative Health. "Together, we are ensuring that thousands of patients have access to the newest available therapies, and that sponsors have a credible, high-performing partner to accelerate cardiovascular trial success." For more information, visit www.iterative.health and https://usheartandvascular.com/.
New weight-loss pill hits the market, promising 'greater flexibility'
FDA approves Foundayo, a once-daily weight loss pill by Lilly. Clinical trials showed adults lost an average of 27.3 pounds on the highest dose, although there are side effects.
Sharing her passion for science
By Danielle Rush Communications Specialist, Indiana University Kokomo Hisako Masuda, Indiana University Kokomo professor of biochemistry, was honored by the Indiana Academy of Science (IAS) as its 2026 Distinguished Scholar. The award is given to an individual who is recognized by the IAS as having an exceptional record of scholarship. Recipients are selected from nominations submitted to its awards committee. “I was surprised,” said Masuda, who joined IU Kokomo’s faculty in 2013. “I feel there are many good scientists in the Academy, so I wasn’t expecting it at all.” Patrick Motl, dean of the School of Sciences, said the Academy recognizes up to one member per year, and that Masuda is the second or third IU Kokomo faculty member to receive the commendation. “Clearly this speaks to the strength of Dr. Masuda’s accomplishments in research and scholarship and that her work stands out amongst her peers in Indiana,” said Motl, who received the award in 2019. “Many of the institutions that participate in the IAS are undergraduate institutions or primarily undergraduate institutions, but even having that caveat, Dr. Masuda has built and maintains a very active research program in her lab, working exclusively with undergraduates. She is passionate about science and can share that passion with her students. To carry on a quality research program with so many students involved in so many projects is truly remarkable and I am glad that the IAS acknowledged that for Dr. Masuda.” The IAS specifically commended her for involving more than 50 undergraduates in her research in bacterial metabolism, genomics, and their phenotypic plasticity at IU Kokomo, and publishing 23 articles with many student co-authors. Masuda’s current work primarily focuses on biodegradation and chemical repurposing of nylon. Using soil bacteria, her lab studies bacterial biodegradation of nylon and other environmental pollutants. She applies principles of green chemistry while developing a method to convert nylon waste into other nontoxic polymers. In collaborative work with health scientists, her lab investigates gut microbiomes of Indiana native birds as well as human subjects in a clinical study. She became interested in converting plastic waste while earning her Ph.D. at Rutgers University, working on methods to remove environmental waste not using chemicals or other intrusive methods. She learned about Nylon 11, which is used in pipes for transferring oil, interior components for cars, catheters, and in other industrial hard plastics. Nylon 11 is nontoxic, she added, so it is safe to include students in the research. “Those are considered to be nonbiodegradable, and have to go to a landfill,” she said. “I thought if we could come up with a way to biodegrade it, that would make some kind of impact.” Eventually, she wants to develop a product that would convert nylon waste to something useful, and to reduce waste and microplastics in the environment. “That would be my goal at some point, that we can make that change, and also make people more aware of their use of plastics,” she said. “I hope students stop to think about what we can do as scientists to address issues currently impacting us.” She appreciates the IAS for its support of scientific research at Indiana institutions, and IU Kokomo and the School of Sciences for providing funding for students to attend the Academy’s annual meeting. She added that IU Kokomo has also supported her research with funding from the School of Sciences and Academic Affairs. “Without that, I couldn’t do my research,” she said. Masuda has also earned a Senior Research Grant from the IAS, IU Kokomo’s Distinguished Research Award, and the IU Kokomo Junior Faculty Annual Research Award. She is a Fellow of the Indiana Academy of Science. Education is KEY at Indiana University Kokomo.
Panoramic Health and West Coast Kidney Institute Launch Concord Cardio-Renal Research Institute to Advance Clinical Trials in Cardio-Renal-Metabolic Disease
/PRNewswire/ -- Panoramic Science, the clinical research division of Panoramic Health, and West Coast Kidney Institute today announced the launch of the...
We’re Spending Billions on Collagen. Here’s What the Science Actually Says
We’re spending billions on powders and gummies, but is it a waste of money? Discover what recent clinical studies from Harvard and FSU reveal about collagen's actual impact on skin, joints, and aging.
HHS Is Exiling Top Officials to the Indian Health Service
The Indian Health Service needs more clinical workers. The federal health officials being transferred to the agency don’t fit that bill.
Mount Sinai Health System Collaborates with OpenEvidence to Provide Evidence-Based Knowledge Within Electronic Medical Record
Collaboration extends access to all clinical users, including nurses and pharmacists
Kettering Health Greene Memorial Celebrates 75 Years
Kettering Health Greene Memorial is celebrating its 75th year in Xenia, a legacy marked by advancements in clinical excellence and strong community ties.
Cannabis-related health problems: WA clinical snapshot - UW Medicine
News and information for journalists
A Nurse Educator on Resilience, Patient Care and the Future of Health - Newsroom | University of St. Thomas
Faculty member Dr. Vane Gichana brings a blend of clinical judgment and critical thinking when she instructs nursing students at St. Thomas.
New £1.5m research facility plan for New Cross Hospital
A new clinical centre will bring big benefits for patients, staff and the health system, say bosses.
Michigan Medicine study shows emoji usage increasing in electronic health records
The study published Jan. 14 analyzed clinical notes from electronic health records and found clinicians are using emojis more often.
UCLA's first dean for Health AI Strategy and Innovation takes office
“The creation of an associate dean in AI speaks to the fact that AI has become central to research, education and clinical operations in the health care system."
UCLA's first dean for Health AI Strategy and Innovation takes office
“The creation of an associate dean in AI speaks to the fact that AI has become central to research, education and clinical operations in the health care system."
Ingredion and Holobiome map gut microbiome to unlock targeted health benefits
Ingredion has partnered with Holobiome to use AI and its database of two million bacterial genomes to predict how specific ingredients will interact with human health before clinical trials. The research expands beyond digestion to explore how sweeteners, plant proteins, and texture solutions influence the gut-brain axis, including sleep and mental health.
The Guardian view on peptides: Robert F Kennedy Jr would leave public health policy to the hucksters
Editorial: The US health secretary says he is a big fan of peptides. Many are promising drugs, but the only way to know their utility is proper clinical trials
Inside the high-stakes business battle over feeding preterm babies
A clinical trial among preterm babies gives a view into corporate warfare in the high-stakes business of infant nutrition.
Boston Children's enhances care with clinical intelligence platform
Two of the hospital's physicians explain how the decision support technology aggregates patient signals to indicate health trajectories – which tells clinicians when to evaluate a patient's evolving state and determine an appropriate response.
PhysioNet as a global platform for biomedical research
Nature Health - Twenty-five years after its first public repository was established, the PhysioNet resource for biomedical and clinical data has enabled tens of thousands of research papers....
UT Health San Antonio launches clinical trial to study rapamycin and healthy aging - UT Health San Antonio
Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu Content provided by Claire Kowalick SAN ANTONIO, March 25, 2026 – UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio) is launching a multi-phase clinical study to better understand how the drug rapamycin may promote healthy aging. Funded by the National […]
UCLA Health receives $2.4 million from Rose and Allen Nelson to establish a fellowship in translational and clinical neuroscience
The gift is being made in memory of their son Brandon, who received his bachelor’s in aerospace engineering from UCLA in 2014.
Pharma bribery corrupts health care, puts patients at risk, new review warns
Sham clinical studies, slush funds and shell companies: A new review shows how pharma firms allegedly bribed their way to drug approvals and sales.
UT Health San Antonio Multispecialty and Research Hospital treats first clinical trial participant in novel cancer study - UT Health San Antonio
Milestone paves the way for advancements in cancer care, innovation and patient care in San Antonio and South Texas. UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer study, marking a pivotal moment for science and patient-centered cancer care in San Antonio and […]
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
Premier 714-bed teaching hospital and Level I Trauma Center purchases ENvue™ Navigation Platform system and feeding tubesTYLER, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced a purchase of the ENvue™ Navigation Platform and feeding tubes by a premier t
Dean for Basic Science Colin Duckett tapped to serve as Boston University Provost
Duckett, executive vice dean for basic and preclinical science, will begin his tenure as chief academic officer at Boston University starting in July.
Your Thymus and Your Healthspan
Our thymus gland plays a central role in the development or our immune system, specifically for supporting T cell development (how these cells got their name, maturation and differentiation in the thymus) and discriminating between self and foreign, non-self antigen proteins with production of dendritic cells. As we age, our thymus gland shrinks—the process known as involution—with progressive change from spongy to fatty tissue, with loss of functionality. But this process, with respect to timeline and extent, markedly varies from one person to the next. And to make things even more complicated, our thymus gland anatomy and precise location in the chest also is highly variable. So the famous Frank Netter diagrams from the 1960s (such as at left below) don’t capture the remarkable heterogeneity that a random set of 12 chest CT scans (below at right). What I consider as 2 landmark papers in Nature this week (here and here) used AI to quantify health of the thymus in 2 large cohorts, and then correlate the metric to a broad array of health outcomes. In this edition of Ground Truths, I’m going to cover three questions: (1) How was thymus health determined by AI?; (2) How is thymus health linked to key clinical outcomes? and (3) Are there ways we can promote a healthy (aka rejuvenate) thymus gland in our later years? Subscribe 1. How was thymus health determined by AI? This was accomplished by extensive work developing and validating an AI pipeline for 2 stages, the first for localization and segmentation of the thymus bed, and the second to quantify a digital marker, termed the thymic health score. There’s a lot to this algorithmic development, so I won’t go into all the details, but just provide a rudimentary outline of what was done. The 1st stage used supervised learning with 2 radiologists reviewing 2,461 chest CT scans. That work trained a 3D U-Net model to automatically identify the thymic bed’s 3D cropped region using center of mass coordinates, which reached 99.8% accuracy. The 2nd stage used a foundation model that was pre-trained with SwAV (which stands for Swapping Assignment between multiple Views), a self-supervised model, that generated a high-dimensional thymus representation of 4,096 features. That compares to the radiology reductionist and subjective scoring of 0 to 3 where 0 means the thymus is fully degenerated and fatty, and 3 is considered dense, intact glandular soft tissue. Notably, the self-supervised learning (SSL) performance was superior to supervised (AUC ~0.75 vs 0.55, respectively) reflecting the shallowness of the 0-3 classifier vs SSL’s holistic, self-taught AI. The thymic health score ranged from 0 to 100, with the highest number indexed to fully preserved thymic health. The algorithmic work extended to explainability with both Shapely value distribution, meaning the model was holistic not relying on any “magic” pixel, and occlusion sensitivity, demonstrating the model’s performance was not affected by ribs, sternum, lung tissue, but rather focused on the thymic bed directly. Below are a few saliency maps from the occlusion sensitivity that indicate the thymic bed focus, not affected by neighboring structures, using the jet color scale. Now the AI was ready for processing ~25,000 CT scans, each over 30 MB files, from the 2 large participant cohorts to provide a thymic health score, it did so in less than 14 hours, which is less than 2 seconds per scan! Share 2. How is thymus health linked to key clinical outcomes? The two cohorts were the National Lung Screening Trial, NLST (N=25,031) and the Framingham Heart Study, FHS (N=2,581) each with baseline demographics and long term follow up of >12 years for health outcomes. From the NSLT, you can see below that increased age and body-mass index were correlated to reduced thymic health. And, overall, men had reduced thymic health scores compared with women. There are a lot of graphs in the paper for outcomes, for both the NLST and FHS cohorts. To simplify the major outcomes, below is a composite Figure with striking reduction of all-cause mortality and for the different causes of death. The results were consistent between the 2 cohorts. For example, the cardiovascular mortality hazard ratio average was 0.57 in NLST and 0.38 in FHS (weighted to be 0.53 for the aggregate). The reduction of mortality also extended to digestive diseases and pulmonary disease (data not shown below). Lung cancer incidence was reduced by 36% for high vs low thymic health (Figure below, with a panel -incidence and b panel-mortality, adjusted for age, sex, BMI, smoking status). Notably, there was a smoker’s paradox: lower incidence and improved survival for lung cancer in smokers who had a high thymus health score. Smoking was associated with lower thymic scores whereas alcohol was not. Higher thymic health was linked to higher HDL cholesterol, lower triglycerides, lower fasting blood glucose, and lower systolic and diastolic blood pressure. Inflammation biomarkers, such as C-reactive protein and interleukin-6, were elevated in the people with lower thymic health scores. In their second paper, the same team looked at the relationship between thymic score and outcomes for 3,476 patients receiving cancer immunotherapy. The non-small cell lung cancer progression-free survival was reduced in patients with low thymic health score. A parallel relationship for survival was seen for other types of cancer including melanoma, breast, and kidney with a 44% lower risk among high thymic scores (Figure). A similar pattern was seen with different immune checkpoint inhibitors. The thymus health score outperformed programmed death ligand-1 (PD-L1)and tumor mutation burden (TMB) assay of the tumor and was an independent prognostic marker of progression-free survival. In this dataset, a direct connect with thymus score and adaptive immune function was noted with a correlation before cancer treatment for both T-cell diversity and thymus T-cell production (a metric known as T cell receptor excision circles). Thymus Removal Study There is a highly relevant citation about thymus function before moving onto ways to rejuvenate it. In 2023, a very important study of thymus removal during cardiothoracic surgery was published, with 1146 patients undergoing thymus removal vs 1146 matched controls (mean age 55 years). The adverse outcomes for thymus removal were striking, with a 2.9 higher risk of all-cause mortality and doubling of cancer incidence, 1.5 fold increase in cancer mortality, and 1.5-fold increase in autoimmune diseases. The immune function showed marked compromise after thymus removal, as reflected by CD4+ and CD8+ T cells (Figure below) Share Ground Truths 3. Are there ways we can promote a healthy (aka rejuvenate) thymus gland in our later years? In recent months we’ve learned a lot about the process of thymus involution and the pathways by which this may be modulated. Thymus involution is primarily due to loss to thymus epithelial cells (TECs) and there are 2 subtypes with different functions: the cortical, responsible for positive selection of T cells, and the medullary, for negative selection. When adipose tissue infiltrates the thymus, thymic adipocytes are pro-inflammatory, knocking out T-cell output. Likewise, systemic inflammation, or “inflammaging,” from smoking, obesity, and chronic stress promote thymic adipocytes. Now, from preclinical studies, we know about key pathways that account for these processes. Historically, back in 2014, FOXN1 was recognized as a single master transcription factor essential for TEC function, with studies in mice with forced FOXN1 upregulation leading to thymus regeneration. That laid the foundation for potential regrowth of quiescent thymus cells. It took awhile to find pathways to accomplish this goal and to even refute its role as the master regulator. The Liver-Thymus Axis Feng Zhang and his team recently showed that injection of an mRNA vaccine to the liver encoding DLL1, IL-7 and FLT3-L in combination, factors known to support thymopoiesis (Figure), successfully enhanced immune function in aged mice. However, the effect was transient. The FGF21 Story Two reports in 2025 addressed the thymus gland’s production of FGF21, a growth factor (fibroblast growth factor 21) and its control of thymus involution. This growth factor is also produced by the liver, but it doesn’t have impact on the thymus in aged rodent models. In contrast, The liver’s hepatocyte growth factor (HGF) has been shown to reverse senescent TEC structural changes. Growth hormone stimulates production of insulin growth factor-1 (IGF-1) in the liver and the thymus. Two small studies in human participants (TRIIM, for Thymus Regeneration, Immunorestoration, and Insulin Mitigation) of 6 and 50 people, respectively, treated with combined human growth hormone, metformin and DHEA, suggested the potential of slowing epigenetic aging and improving thymus mass and function. But the combination of drugs, small sample, and lack of controls make conclusions murky. Increased thymus FGF21 led to increased CD8 T cells in old mice and extended healthspan and improved physical performance. Building on the previous FOXN1 data, ablation of β-klotho, the obligatory co-receptor for FOXN1, accelerated thymic aging. The benefit to FGF21 was confirmed in a companion paper using an FGF21 knock-in mouse model showing thymus enlargement and increased TECs throughout the lifespan. (schematic Figure below). The accompanying editorial for these 2 papers speculated: “The proposed link between age-associated thymus involution and organismal aging is intriguing, and suggests we might seek to achieve systemic rejuvenation by counteracting thymic involution.” Other Factors Lessons from the Axolotl (Mexican Salamander) In an elegant set of experiments of the axolotl (Figure), known for its complete thymus regeneration after total surgical removal, mediators were identified. Surprisingly FOXN1 was dispensable. But midkine, a growth factor, appeared to be the driver, the initiator of thymus cell growth, survival, and repair. Other components that contributed were Postn+ (periostin-expressing mesenchymal niches) and Ccl19, a chemokine protein from the bloodstream. RANK and RANKL RANK (receptor activator of nuclear factor κB its ligand (RANKL) have been considered key regulators of medullary TECs. In a study of both aged mice and human thymus cell cultures, their key role was confirmed, with multiple benefits of resorting TEC function, recruitment of progenitor cells, and T cell development. Subscribe Summing Up This body of work strongly supports the health of the thymus gland as a critical regulator of human healthspan, not just a correlate or link. The new landmark studies are reinforced by the regenerative biology experimental models that have shown, via an array of mediators, that healthspan of aged mice is at least in part dependent on thymus gland function and its critical role for maintaining adaptive immunity. It sure seems that we’d be better off having an immune reservoir of naive T cells instead of a profile in older adults of exhausted, low quality, memory T cells, with a senescent phenotype. It is striking that we ignored the importance of the thymus gland for many decades. A wake-up call was the results of the thymectomy matched control study reviewed here, with the opposite of high thymic health score improved health outcomes. The convergence of AI and healthspan here is notable. The exceptional and laborious work for developing and validating (no less explaining) the AI to quantify thymus health set the foundation for probing the connect the major health outcomes in two cohorts with extensive follow-up. We’ve never had a way to meaningfully quantify the thymus gland before, so this represents important leverage of supervised, self-supervised, and transformer models. The study wouldn’t have been possible without AI. And it begs the question as to whether there are ways we can maintain our thymus at a high health score. But it’s not so simple to rejuvenate our thymus. There are multiple risks including the induction of autoimmunity, increasing the risk of cancer, and inducing a pro-inflammatory state. For example, factors that increase TEC proliferation could compromise the medulllary negative selection process and leak out auto-reactive (self-attacking) T cells. Thymic cells could be induced to proliferate, but we know, for example, that growth hormone and IGF-1 are associated with an increase risk of cancer. If thymus rejuvenation doesn’t clear out the accumulated senescent cells in older adults, then inflammation within the gland could block the production of TECs. Keeping these risks in mind, we now have identified many ways to keep our thymus healthy as we age that undoubtedly will be tested in clinical trials going forward. Ultimately, the benefit-to-risk tradeoffs will be defined. In the meantime, we have desperately needed an immunome. As I’ve stressed in multiple prior Ground Truths, we have no test in the clinic to assess a patient’s immune status! It was very encouraging for me to get an email from Hugo Aerts, the senior author of the landmark papers in the days after they were published: “I also wanted to say that your Substack on “Why We Need an Immunome” was inspiring for this work. We found it a very compelling perspective and greatly enjoyed reading it.” Just having an assessment of a person’s immune status via a chest CT scan, with millions of these performed per year, might help in guiding the right immunotherapy for cancer (e.g. more intensive, combinations for those with low thymic health scores) and help define people who are increased risk for age-related diseases of cancer, cardiovascular, and neurodegenerative. The main theme of Super Agers is that we now have many layers of data (genetics, proteins, biomarkers, organ clocks that can be integrated via multimodal AI) for us to define a person’s specific risk decades before one of these age-related diseases leads to symptoms, enabling prevention. From the new studies this week, we can add thymus health score as yet another way to understand a person’s risk, a window into their adaptive immune system and healthspan. And perhaps someday we will be able to safely rejuvenate the thymus, or maintain its health through one’s life, and use the thymus health score to monitor. NB: I wrote this post (No A.I.) A Quick Poll Loading... ********************************************************************* Thanks to Ground Truths subscribers (now > 200,000) from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join! If you found this interesting PLEASE share it! Share Ground Truths Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered. Leave a comment Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.
Health Literacy as a Modifiable Clinical Risk Factor: Operationalizing an Underrecognized Determinant of Outcomes
Health literacy has been considered a social determinant of health and has never been extensively incorporated in the general practice of clinical care. Systematic reviews and cohort studies sho...
Healthcare employee health plan bridges the gap between data and action
Integrating UpToDate evidence-based clinical decision support helps health plan optimize costs and member-centered care.
A biotech turns to Apple Watch to study its Parkinson's drug
In this edition of STAT Health Tech: How Apple Watch is being used in a clinical trial for a Parkinson's drug, and more
Forum on harnessing Artificial Intelligence for health equity
Register to this forumOver the past decade, artificial intelligence (AI) has significantly evolved in complexity, performance, and utility. Its integration across a wide range of industrial sectors has accelerated, with healthcare emerging as one of the most transformative sectors. In this sector, AI has enabled high-impact applications – from enhancing the speed and accuracy of disease diagnosis and supporting clinical decision-making, to strengthening public health initiatives such as disease surveillance and workforce optimization. Moreover, AI holds immense potential to empower individuals, enabling them to take greater control of their personal health and well-being. Yet the central question remains: Who benefits, who is at risk, and do these innovations close or widen health inequities? While the potential of AI-enabled applications is substantial, many countries have approached their adoption with caution. This hesitancy stems from concerns about risks and benefits, including model bias, data breaches, privacy violations, and the erosion of professional skills due to over-reliance on AI. Additional barriers include inadequate data infrastructure and a lack of robust evidence on the most effective forms and interfaces of AI to enhance service delivery and system performance. Moreover, the rapid rise of Generative AI has introduced a heightened urgency for the development of comprehensive governance and ethical frameworks. The Asian Development Bank (ADB) Health Practice Team and Digital Sector, in collaboration with the World Health Organization (WHO) Regional Office for the Western Pacific, are convening the Forum on Harnessing AI for Health Equity on 25–26 March at ADB Headquarters. Senior health officials from 16 developing member countries (DMCs), alongside leading researchers, innovators, and policymakers from across Asia and the Pacific, will engage in discussions on how AI can be governed, financed, and scaled to deliver healthier lives for all. The forum is funded through the High-Level Technology Fund with support from the Government of Japan. Objectives The two-day forum aims to:Identify high-impact, evidence-based health AI use cases suitable for resource-constrained settings and map out a pipeline for potential supportIntroduce and validate the WHO's policy guidance on minimum necessary ecosystem for countries and institutions to self-assess readiness for AI adoptionObtain initial commitment from participating stakeholders to join a pilot regional initiative focused on data/model sharing for a priority health challengeEndorse a prioritized set of actionable policy recommendations focusing on governance, regulation, and sustainable financing necessary to scale high-impact health AI use cases in resource-constrained settings Target participants The forum will convene participants from 16 ADB DMCs including Bangladesh, Bhutan, Cambodia, Cook Islands, Fiji, Indonesia, Lao People's Democratic Republic, Mongolia, Nepal, Palau, Papua New Guinea, Philippines, Sri Lanka, Thailand, Uzbekistan, and Viet Nam. In addition, health system leaders and practitioners, private sector technologists, academic experts, representatives from civil society organizations, development partners, and philanthropic institutions engaged in AI for Health from Australia, the People’s Republic of China, Japan, Malaysia, New Zealand, Singapore, and the Republic of Korea will also be invited. SessionsDay 1 (25 March)Session 1: AI Use Cases for the Care Continuum: Improving Access and QualitySession 2: Adopting a risk-based approach for AI use case prioritizationSession 3: Establishing the Minimum Ecosystem for Implementation Risk ManagementSession 4: Future-Ready Health Workforce: Building Competency for Human-AI CollaborationDay 2 (26 March)Session 5: The Political Economy of AI in Health: Understanding Stakeholder Interests and their Impact on EquitySession 6: AI and Health Financing: Supporting Fair Coverage and ProtectionSession 7: AI Regulation and Oversight: Pathways for Different RealitiesSession 8: The Way Forward – Building Alliances and Regional Partnership How to registerThe forum will be held in a hybrid format. In-person attendance is by invitation only, while livestreaming of the forum will be available to the public. To register, please complete this form on or before 24 March 2026.Event organizers / partnersAsian Development Bank (ADB)WHO Regional Office for the Western Pacific High-Level Technology Fund (HLTF)ContactAkihito WatabeHealth Specialist, SD3-HSDawatabe@adb.org Jae Kyoun KimHealth Specialist, SD3-HSDjkkim@adb.org
Messi scores 900th career goal in Inter Miami cup clash
Argentine superstar Lionel Messi bagged the 900th goal of his glittering career on Wednesday, scoring for Inter Miami in their CONCACAF Champions Cup clash with Nashville.- Clinical finish - The Argentine World Cup winner's 900th goal came early in Miami's last-16 second leg tie with MLS rivals Nashville.
Different uniform, same mission
Tim Barnes, the clinical manager for radiation oncology, has spent 17 years with ECU Health, but started his career in law enforcement.
Do Diet Trends Improve Health? A Clinical Take
Learn which diet trends have scientific support — clean eating, detox, glow food and plant-based diets influence health differently and require individualized clinical counseling.
Sparse evidence for cannabis to treat mental health conditions highlights research gap
A new analysis represents the largest effort yet to systematically parse all the data from high-quality clinical trials on cannabis and mental health. The evidence is lacking.
Rochester Regional Health Launches Targeted Loan-Support Program to Strengthen Access to Critical Healthcare Services
Rochester Regional Health (RRH) today announced a targeted student-loan support program designed to strengthen access to essential clinical care across the region. Through a partnership with Clasp, Rochester Regional will help future Certified Registered Nurse Anesthetists (CRNAs), Surgical Technologists, and Radiologic Technologists finance their education and begin their careers serving the patients of Rochester and the Finger Lakes Region.
Large rapamycin clinical trial launches at UT Health San Antonio - UT Health San Antonio
A drug once known almost exclusively for preventing organ transplant rejection is now at the center of a National Institute on Aging-funded clinical study at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), to determine how rapamycin should be used in older adults to […]
Just 24 minutes of specially designed music could significantly reduce anxiety
A clinical trial found that listening to specially designed music with auditory beat stimulation can significantly reduce anxiety. Among several listening lengths tested, a 24-minute session delivered the biggest benefits, easing both mental and physical symptoms of anxiety. The results suggest there may be an ideal “dose” of therapeutic music that works quickly without requiring long listening sessions.
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Can a groundbreaking cancer therapy help people with multiple sclerosis?
A handful of small, early-stage clinical trials are investigating whether CAR-T therapy can improve symptoms in multiple sclerosis patients.
Scientists tested vitamin D for COVID and found an unexpected long COVID clue
A major clinical trial has delivered an unexpected twist in the search for ways to fight COVID-19 and its lingering effects. Researchers at Mass General Brigham found that taking high doses of vitamin D3 did not make COVID-19 infections less severe or reduce hospital visits. However, the study uncovered a subtle but intriguing signal suggesting that people who consistently took vitamin D supplements might be slightly less likely to develop long COVID symptoms weeks after infection.
Maine’s wild blueberries deliver more than tradition. Research proves they support health.
Wild blueberries — the iconic Maine crop dotting hillsides, decorating sweatshirts and adding personality to local menus — is more than a cultural symbol. Over 20 years of preclinical and clinical studies suggest that regularly consuming wild blueberries supports gut and heart health and may reduce risk factors associated with…
Researchers develop AI tool to predict patients at risk of intimate partner violence
NIH-funded, automated clinical decision support could facilitate timely interventions for at-risk patients years before they might otherwise seek help.
Clinical trial focuses on reducing fear and improving mental health outcomes in high-risk pregnancies
Study uses therapy and an immersive cesarean rehearsal to help high‑risk pregnant patients reduce fear and improve mental health outcomes.
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live sto